Compare EOG Resources Inc (EOG) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EOG Resources Inc vs Recursion Pharmaceuticals Inc — how do they compare? EOG Resources Inc trades at $148.57 (market cap $75.64B), while Recursion Pharmaceuticals Inc trades at $3.99 (market cap $2.31B). The key difference: EOG Resources Inc is far larger — about 32.7× Recursion Pharmaceuticals Inc's market cap, and EOG Resources Inc pays a 2.83% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold EOG Resources Inc for 59 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| EOG | RXRX | |
|---|---|---|
Market Cap | $75.64B | $2.31B |
Volume | 2,041,336 | 40,478,768 |
Sector | Energy | Health |
52-Week High | $153.74 | $6.79 |
52-Week Low | $101.78 | $2.84 |
Typical Hold Time | 59 Days | 22 Days |
Enterprise Value | $78.99B | $1.83B |
Dividend Yield | 2.83% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EOG Resources trades at $148.51, up 2.93% today, with a bullish technical signal from moving averages and strong fundamental metrics including a P/E of 11.22 and net income margin of 25.81%. The company has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $5.07 exceeding expectations. Recent news highlights robust operational execution and disciplined capital allocation, with a CFO transition announced in September 2026.
Outlook remains positive with a consensus price target of $164.77, offering ~11% upside. Key opportunities include 5% oil volume growth guidance and strong free cash flow generation. Risks involve oil price volatility, as seen in recent price retreats, and execution of leadership transition. The stock presents a compelling value with no sell ratings among 66 analysts.
RXRX trades at $4.27, down 7.78% today, with a bullish technical signal from moving averages but negative profitability. The company reported a net loss of -$644.76M in 2025, with revenue of $74.26M, and has beaten earnings estimates in two of the last three quarters. Recent news highlights strategic AI partnerships and pipeline expansion, though financial performance remains challenged.
The outlook is mixed: analyst consensus is 40% buy, 60% hold, with no sell ratings, indicating cautious optimism for long-term AI-driven growth. Key risks include persistent cash burn, high valuation multiples, and slow revenue growth. Upside depends on successful drug development and partnership milestones, but near-term profitability remains elusive.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About EOG Resources Inc
EOG Resources is an oil and gas producer with acreage in several U.S. shale plays, including the Permian Basin, the Eagle Ford, and the Bakken. At the end of 2021, it reported net proved reserves of 3.7 billion barrels of oil equivalent. Net production averaged 829 thousand barrels of oil equivalent per day in 2021 at a ratio of 72% oil and natural gas liquids and 28% natural gas.
Read more on EOG →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
